In this observational study, we found that combined basal insulin plus GLP1 RA therapy achieved HbA1C level improvement and weight reductions, diminished glucose fluctuation with safety profiles than premixed insulin regimen among patients of T2D who needed intensification to injectable therapy. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.